A new real-world analysis finds that severe infection rates were higher than in clinical trials in 67 patients with CLL or B-cell lymphoma who took ibrutinib, idelalisib, or venetoclax. OncTwitter
A new real-world analysis finds that severe infection rates were higher than in clinical trials in 67 patients with chronic lymphocytic leukemia or B-cell lymphoma who took ibrutinib , idelalisib , or venetoclax .
According to the study, there are limited data about real-world infection rates for patients with CLL or B-cell lymphoma who take the three drugs. Of the 67 patients in the study, the numbers taking the drugs were 53 , 8 , and 6 . Eleven patients took more than one drug. Median age was 73 years, and 73% of patients were male.
In comparison, the researchers reported, a systematic review of idelalisib in blood cancer clinical trials reported an overall infection rate of 28%, while clinical trials reported an infection rate of 17.5%-22% in patients taking venetoclax for CLL. In an interview, infectious disease physician Gemma Reynolds, MChD, MPH, of Austin Health and Peter MacCallum Cancer Center in Melbourne, said the study findings reflect"a lot of what we know from other observational studies and clinical practice. There is a risk of infection, and serious infection, associated with these agents. Sometimes the pathogen is classically opportunistic, but often it is bacterial, and respiratory sites are common.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Ban on certain transgender treatment for Georgia minors marches onA Georgia bill to prohibit medical professionals from administering 'irreversible' gender-affirming care to minors passed a state House committee on party lines Tuesday, prompting tears from transgender rights activists in the room.
Read more »
Robin Roberts Gives Update on Amber Laign's Cancer TreatmentThe veteran TV journalist spoke to ET about the new season of her 'Turning the Tables' series and wedding planning with her partner.
Read more »
Why a nasal vaccine could reduce the risk of COVID infections and new variantsThree years into the pandemic, the World Health Organization's Joachim Hombach talks about the future of vaccines with MarketWatch.
Read more »
Revolutionizing Biotechnology: Scientists Create Supercharged Bacteria with Immunity to Viral InfectionsResearchers create virus-resistant, safely restrained E. coli for medical, industrial applications. In a step forward for genetic engineering and synthetic biology, researchers have modified a strain of Escherichia coli bacteria to be immune to natural viral infections while also minimizing the p
Read more »
Why are sexually transmitted infections on the rise in the US?Carissa Wong is a freelance reporter who holds a PhD in cancer immunology from Cardiff University, in collaboration with the University of Bristol. She was formerly a staff writer at New Scientist magazine covering health, environment, technology, nature and ancient life, and has also written for MailOnline.
Read more »